Joint Formulary & PAD

Olodaterol (Striverdi Respimat) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Soft mist inhaler
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Olodaterol (Striverdi Respimat)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
LABA
Keywords :
Long-acting beta agonists, LABAs, Respiratory disease, bronchodilators
Brand Names Include :
Striverdi Respimat
Important Information :

LABA monotherapy no longer recommended for asthma or COPD.

Not for initiation in new patients.

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
4

Other Indications

Below are listed other indications that Olodaterol (Striverdi Respimat) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (1)

Single device LABA is not recommended in Asthma or COPD.
Combined LAMA/LABA is the bronchodilator treatment of choice for patients with COPD who are breathless or having exacerbations following treatment with SABA.

Existing LABA patients, whose symptoms are under control, can continue with their current treatment until both they and their NHS healthcare professional agree it is appropriate to change.

Inhaler devices should be prescribed by BRAND.

See COPD guidelines below